期刊文献+

培哚普利与美托洛尔治疗糖尿病无症状心功能不全的临床疗效比较 被引量:9

原文传递
导出
摘要 目的研究糖尿病无症状心功能不全患者的脑钠肽(BNP)水平与左室射血分数(LVEF)、Tei指数,比较培哚普利与美托洛尔的临床治疗效果。方法将100例糖尿病无症状心功能不全患者分为2组,培哚普利组50例,起始服用培哚普利2mg/d,2周后改为4mg/d,4周后改为8mg/d,并坚持服用8mg/d,其中有6例不耐受,4例出现中度咳嗽而退出研究;美托洛尔组50例,起始服用琥珀酸美托洛尔缓释片11.88mg/d,2周后改为23.75mg/d,4周后改为47.5mg/d,并坚持服用47.5mg/d,其中有6例心率〈55次/min停止用药。观察用药1年后两组BNP水平、LVEF与Tei指数的变化。结果两组BNP水平与心功能指标都得到明显的改善;培哚普利组的BNP水平与Tei指数明显低于美托洛尔组(PBNP=0.0000,P%=0.042),而培哚普利组的LVEF明显高于美托洛尔组(P=0.000)。结论培哚普利治疗糖尿病无症状心功能不全患者的效果优于美托洛尔。
作者 陈文
出处 《中国医师杂志》 CAS 2013年第4期559-561,共3页 Journal of Chinese Physician
  • 相关文献

参考文献11

  • 1Kannel WB, Hjortland M, Castelli WP. Role of diabetes in con- gestive heart failure: the Framingham study. Am J Cardiol,1974 , 34( 1 ) :29-34.
  • 2Maisel AS, MeCord J, Nowak RM, et al. Bedside B-Type natri- uretic peptide in the emergency diagnosis of heart failure with re- dueed orpreserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coil Cardiol,2003,41 ( 11 ) : 2010-2017.
  • 3Yusuf S, Sleight P, Pogue J,et al. Effects of an angiotensin-con- verting-enzyme inhibitor, ramipril, on cardiovascular events in. high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med,2000,342 (3) : 145-153.
  • 4Shindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus, a pre- dictor of morbidity and mortality in the Studies of Left Ventrieular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol, 1996, 77( 11 ) :1017-1020.
  • 5Stein BC, Levin RI. Natriuretie peptides : physiology, therapeutic potential, and risk stratifieationin ischemie heart disease. Am Heart J, 1998, 135(5 Pt 1 ) :914-923.
  • 6Shimabukuro M, Higa N, Oshiro Y, et al. Diagnostic utility of brain-natriuretie peptide for left ventricular diastolic dysfunction inasymptomatie type 2 diabetic patients. Diabetes Obes Metab, 2007,9 (3) :323 -329.
  • 7Tei C, Ling LH, Hodge DO, et al. New index of combined systolic and diastolic myocardial performance: a simple andreprodueible measure of cardiac function-a study in normals and dilated eardio- myopathy. J Cardiol, 1995,26(6) :357-366.
  • 8Dawson A, Jeyaseelan S, Morris AD,et al. B-type natriuretic pep- tide as an alternative way of assessing total cardiovascular risk in patientswith diabetes mellitus. Am J Cardiol, 2005,96 ( 7 ) : 933- 934.
  • 9Yano Y, Katsuki A, Gabazza EC, et al. Plasma brain natriuretic peptide levels in normotensive noninsulin-dependent diabetic pa- tientswith mieroalbuminuria. J Clin Endoerinol Metab, 1999,84 (7) :2353-2356.
  • 10Braunwald E, Bristow MR. Congestive heart failure: fifty years of progress. Circulation, 2000,102 ( 20 ) : 14-23.

同被引文献92

引证文献9

二级引证文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部